Sign inJoin waitlistJoin the waitlist

William Matsui

Professor of Medicine · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present

Johns Hopkins University School of Medicine
1998–2001
Internal Medicine
University of Washington-Seattle Campus
1995–1996
University of California, San Francisco School of Medicine
1991–1995

Research

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Biology of Blood and Marrow Transplantation · 2008 · 1,627 citations
Characterization of clonogenic multiple myeloma cells
Blood · 2004 · First of 9 authors · Corresponding · 629 citations
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers
Cancer Research · 2007 · 560 citations

CH
Carol Huff
40 papers
Robert Brodsky
32 papers
RA
Richard Ambinder
31 papers
IB
Ivan Borrello
30 papers
BS
Bruce Smith
29 papers
EF
Ephraim Fuchs
28 papers
Leo Luznik
27 papers
JM
Javier Meade
23 papers
LS
Lode Swinnen
21 papers
YK
Yvette Kasamon
21 papers
DG
Douglas Gladstone
20 papers
ZR
Zeshaan Rasheed
17 papers

Grants

Targeting Extracellular Matrix-Cancer Stem Cell Interactions in Pancreatic Cancer
National Cancer Institute · R01
Contact PI · $1.8M · University of Texas at Austin
2016–2024
Molecular Targets for Cancer Detection and Treatment
National Cancer Institute · T32
PI · $1.1M · Johns Hopkins University
1979–2021
Mentoring and Research in Cancer Stem Cells
National Cancer Institute · K24
Contact PI · $933.2K · University of Texas at Austin
2016–2021
Role of Multiple Myeloma Cancer Stem Cells in Clinical Disease
National Cancer Institute · R01
Contact PI · $2.3M · Johns Hopkins University
2014–2019

Clinical trials

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2024–2031